Pfizer Ltd. — Regulatory Filings 2022

May 20, 2022

Pfizer Limited

The Capital, 1802/1901, Plot No. C - 70, G Block, Sandra Kurla Complex, Sandra (East), Mumbai 400 051. Tel: +91 22 6693 2000 Fax: +91 22 2654 0274

May 20, 2022

The Corporate Relationship Dept. BSE Limited 1st Floor, P.J.Towers Dalal Street, Fort Mumbai - 400 001 Scrip Code: 500680

The Manager, Listing Dept. The National Stock Exchange of India Ltd. Exchange Plaza, 5th Floor, Plot No. C/1, G Block Bandra-Kurla Complex, Bandra (E) Mumbai - 400 051 Scrip Symbol: PFIZER

Dear Sirs,

Sub: Audited financial results and Audit Report for the financial year ended March 31, 2022 - Outcome o,f Board Meeting - Regulation 30.

Pursuant to Regulation 33 of the SEBI (Listing Obligation Disclosure Requirements) Regulations, 2015, we submit herewith audited financial results for the financial year ended March 31, 2022, Statement of Assets and Liabilities as on March 31, 2022, Statement of Audited Cash Flows for the year ended March 31, 2022, Declaration with respect to Audit Report with unmodified opinion and the Auditor's Report by Auditors, M/s. Walker Chandiok & Co LLP, which were approved by the Board of Directors of the Company at its Meeting held today, that commenced at 5.00 p.m. and concluded at 7.15 p.m.

The Board of Directors have at its Meeting held today, i.e., May 20, 2022, recommended a dividend of Rs. 35/- per equity share of Rs. 10/- each {350%) for the financial year ended March 31, 2022. The said dividend, if declared at the ensuing Annual General Meeting of the Company shall be paid on or before September 23, 2022.

Further, please be informed that the Statutory Auditors of the Company, M/s. Walker Chandiok & Co LLP would be completing their term of 5 years at the ensuing Annual General Meeting ofthe Company. Consequently, based on the recommendation of the Audit Committee of the Company, the Board of Directors ofthe Company at its meeting held today, i.e., May 20, 2022, recommended appointment of M/s. B S R & Co. LLP, Chartered Accountant (Firm Registration No. 101248W/W-100022) as the Statutory Auditors of the Company. Accordingly, M/s. BS R & Co. LLP will hold office for a period of 5 (five) consecutive years from the conclusion of the ensuing 71st Annual General Meeting of the Company till the conclusion of the 76th Annual General Meeting subject to the approval of the shareholders of the Company.

CIN: L24231MH1950PLC008311 Email ID: contactus.india@pfizer.com Website: www.pfizerindia.com

We request you to kindly take the same on record.

Thanking you,

Yours truly, For Pfizer Limited

Praff-

Company Secretary

Encl: A/a

Cc: National Securities Depository Limited (NSDL) Central Depository Services (India) Limited (CDSL) KFin Technologies Limited